Two of the best-performing stocks in our portfolio over the last year or so have been Eli Lilly and Novo Nordisk, due to their successful obesity drug rollouts. The question is whether there is more growth to come or if the share prices have run too far. Both have taken 1st-generation drugs that had daily
The post Morningstar’s bear take on obesity drug manufacturers appeared first on MacroBusiness.